Correlation between ratios of brachytherapy source dwell times to dose restriction volumes in cervical cancer treatments
DOI:
https://doi.org/10.35954/SM2021.40.1.2Keywords:
Brachytherapy, Uterine Cervical Neoplasms; Uterine Neoplasms; Radiation Oncology; RadiotherapyAbstract
Cervical cancer is traditionally treated with radiation therapy, worrying about giving a high dose of radiation to the tumor while keeping the organs healthy at the lowest possible dose. Radiation therapy in these treatments is commonly done in two phases, teletherapy and brachytherapy, it is needed to add the doses given in each of them for both, the tumor and healthy tissues. Isodose in brachytherapy are formed from the dwell time source inside the device that is located in the uterine cavity, it is sought in this work from these downtimes to explore the option of using these permanence times as tools to assess the dose that reaches healthy tissues. The dimensions of isodose are studied in the direction of three axes, h, w and t and the ratios of them are correlated with the times ratio of the dwell times times in the uterine and vaginal area, seeking to see the feasibility of using these times as dose evaluation parameters in healthy organs. It is found that the correlation of the dimensions ratio with the time ratio is in the range of strong and moderate with a considerable level of statistical significance, which allows to consider the use of times as a feasible dose evaluation tool for the organs at risk.
Received for review: January 2021.
Accepted for publication: March 2021.
Correspondence: Cátedra Oncología Radioterápica, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Avenida Italia S/N, C.P. 11600. Montevideo, Uruguay.
Contact e-mail: ghpiriz@gmail.com
Downloads
References
(1) Organización Mundial de la Salud. Cancer [Sitio Web]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/cancer [Consulta 15/10/2020]
(2) Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical Cancer Prevalence, Incidence and Mortality in Low and Middle Income Countries: A Systematic Review. Asian Pac J Cancer Prev 2018; 19(2):319-324. doi: 10.22034/APJCP.2018.19.2.319
(3) Saei Ghare Naz M, Kariman N, Ebadi A, Ozgoli G, Ghasemi V, Rashidi Fakari F. Educational Interventions for Cervical Cancer Screening Behavior of Women: A Systematic Review. Asian Pac J Cancer Prev 2018; 19(4):875-884. doi: 10.22034/APJCP.2018.19.4.875
(4) Comisión Honoraria de Lucha contra el Cáncer. Situación Epidemiológica del Uruguay en relación al Cáncer, mayo 2020. [Sitio Web]. Disponible en: https://www.comisioncancer.org.uy/Ocultas/Situacion-EpidemiologicadelUruguay-en-relacion-al-Cancer--Mayo-2020-uc108 [Consulta 19/09/2020]
(5) Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000; 48(1):201-11. doi: 10.1016/s0360-3016(00)00497-1
(6) Chassagne D, Dutreix A, Almond P, Burgers JMV, Busch M, Joslin CA. ICRU Report 38: Dose and Volume Specification for Reporting Intracavitary Therapy in Gynecology. J. of the ICRU 1985; 20(1):20-22. https://doi.org/10.1093/jicru_os20.1.20
(7) Shrivastava R, Umbarkar RB, Sarje MB, Singh KK. Rectal dosimetry in intracavitary brachytherapy by HDR at rural center of Maharashtra: Comparison of two methods. J Med Phys 2009; 34(2):93-6. doi: 10.4103/0971-6203.51936
(8) Grigsby PW, Williamson JF, Clifford Chao KS, Perez CA. Cervical tumor control evaluated with ICRU 38 reference volumes and integrated reference air kerma. Radiother Oncol 2001; 58(1):19-23. doi: 10.1016/s0167-8140(00)00304-2
(9) Datta NR, Kumar S, Das KJ, Pandey CM, Halder S, Ayyagari S. Variations of intracavitary applicator geometry during multiple HDR brachytherapy insertions in carcinoma cervix and its influence on reporting as per ICRU report 38. Radiother Oncol 2001; 60(1):15-24. doi: 10.1016/s0167-8140(01)00352-8
(10) Cetingöz R, Ataman OU, Tuncel N, Sen M, Kinay M. Optimization in high dose rate brachytherapy for utero-vaginal applications. Radiother Oncol 2001; 58(1):31-6. doi: 10.1016/s0167-8140(00)00295-4
(11) Kannan RA, Gururajachar JM, Ponni A, Koushik K, Kumar M, Alva RC, et al. Comparison of manual and inverse optimisation techniques in high dose rate intracavitary brachytherapy of cervical cancer: A dosimetric study. Rep Pract Oncol Radiother 2015; 20(5):365-9. doi: 10.1016/j.rpor.2015.05.003
(12) Haie-Meder C, Pötter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005; 74(3):235-45. doi: 10.1016/j.radonc.2004.12.015
(13) Pötter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006; 78(1):67-77. doi: 10.1016/j.radonc.2005.11.014
(14) Viswanathan AN, Beriwal S, De Los Santos JF, Demanes DJ, Gaffney D, Hansen J, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy 2012; 11(1):47-52. doi: 10.1016/j.brachy.2011.07.002
(15) Guinot JL, Pérez-Calatayud J, Azcoaga JM, Herruzo I, Bodineau C, Rovirosa A, et al. Consenso en tratamiento del carcinoma de endometrio con braquiterapia grupo de braquiterapia de la SEOR y de la SEFM. Málaga, 11 de marzo de 2011. Disponible en: https://silo.tips/download/consenso-en-tratamiento-del-carcinoma-de-endometrio-con-braquiterapia [Consulta 20/03/2020]
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
